Pfizer (NYSE:PFE) oncology updates and IBRANCE expansion unfold within S&P 500 healthcare segment, alongside lung cancer ...

Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and ...

A vaccine that hits the tick rather than the germ carries one big advantage. Ticks deliver more than Lyme. The same bite can ...

At least two companies in the United States, both with Massachusetts ties, are developing first-of-their-kind shots that ...

Alphabet will replace Verizon Communications in the Dow Jones Industrial Average next week, S&P Dow Jones Indices announced ...

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases ...

Adults 65 and older, along with people ages 5 through 64 who face elevated risk from COVID-19, now have access to an updated vaccine matched to a strain that has been circulating widely. The FDA ...

NEW YORK, June 6 (Reuters) - Pfizer (PFE.N), opens new tab presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its purchase of Metsera last year ...

PFE trades at just 8x forward earnings while paying a near-7% dividend yield, and the five-year base case model targets $49. Pfizer's Berobenatide GLP-1 posted 16% weight loss at 32 weeks with no ...

DIA may be a flawed Dow ETF: opaque DJIA committee and price-weighted distortion underweight mega-cap tech. Read more macro ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 clinical ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...